Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05638802 · ClinicalTrials.gov registry record · Phase 1
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT05638802 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 26 participants.
The verdict
NCT05638802, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Interventions
- DRUG Placebo
- DRUG DS-7011a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05638802
The ClinicalTrials.gov registry entry for NCT05638802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05638802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05638802 about?
NCT05638802 is a clinical study titled "A Study of DS-7011a in Patients With Systemic Lupus Erythematosus". Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for...
What is the current status of trial NCT05638802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-06-07. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT05638802?
The interventions under investigation include: Placebo (DRUG), DS-7011a (DRUG).
Who is sponsoring clinical trial NCT05638802?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.